Latest Conference Articles

The 10th annual meeting of the Family Heart Global Summit will bring together leading scientists and practitioners with patients to discuss treatment of inherited lipid disorders.

At AIDS 2024 in July, Kelly Dyer, MD, Perelman School of Medicine, presented research findings from an investigation at the intersection of health equity, substance use detox, infectious disease screening, and patient harm reduction.

Jennifer Cocohoba, PharmD, MAS, AAHIVP, University of California, San Francisco, School of Pharmacy, discusses the benefits of pharmacy-administered long-acting injectable antiretroviral therapy for HIV and patient attitudes toward pharmacy-administered treatment.

At an Institute for Value-Based Medicine® (IVBM) event cohosted by The American Journal of Managed Care®, experts discussed efforts to implement obesity management science into practice.

A trio of posters presented at AIDS 2024, the 25th International AIDS Conference, explored widespread disparities in access to pre-exposure prophylaxis (PrEP) and how to make access more equitable, both globally and locally.

For the recent AIDS 2024 conference, we spoke with Nishita Dsouza, PhD, MPH, Columbia University School of Social Work Social Intervention Group, who presented research on HIV and sexually transmitted infection prevention among Black women with criminal legal system involvement.

In part 1 of our interview with Anna Sureda, MD, PhD, president of the European Group for Blood and Marrow Transplantation, she summarized the current treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular lymphoma (FL).

In part 1 of this interview, Musarrat Perveen, regional coordinator at Coordination of Action Research on AIDS and Mobility in Asia (CARAM Asia), explained the research she presented at the 25th International AIDS Conference and the disparities migrant workers continue to encounter in HIV care.

A session on the final day of the 2024 Congress of the American Society of Preventive Cardiology explored the connections between autoimmune disease and cardiac events.

We spoke with Musarrat Perveen, regional coordinator at Coordination of Action Research on AIDS and Mobility in Asia (CARAM Asia), who advocates at regional and global levels for policy reform of discriminatory practices that put migrant workers at risk of HIV and AIDS.

A debate on whether testing Lp(a) levels is actionable in primary prevention today offered lively discussion at the 2024 Congress of the American Society for Preventive Cardiology, being held in Salt Lake City, Utah.

A joint session with the Society for Cardiovascular Computed Tomography (SCCT) took place on the first day of the American Society for Preventive Cardiology 2024 Congress in Salt Lake City, Utah.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, outlines future steps for the clinical development of rilzabrutinib, as well as promising data to advance to phase 3 studies.

This research presented at AIDS 2024 shows that cognitive behavioral therapy (CBT) groups help to fill an unmet need among older persons living with HIV: to overcome the age-related health disparities this group experiences from being in long-term care and improve their health outcomes.

Patricia Cioe, PhD, presented data at AIDS 2024 from a study that investigated the impact of peer support on people living with HIV who smoke, a group for whom there are higher rates of cardiac events and cancer.

These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.

A late-breaking abstract focused on a head-to-head comparison between dolutegravir/lamivudine (DTG/3TC) and bictegravir/emtricitabine/tenofovir (BIC/FTC/TAF) in the treatment of HIV.

Two posters presented at the Society for Pediatric Dermatology Annual Meeting explored common health conditions linked to childhood alopecia areata and the effectiveness of dupilumab treatment in children with both alopecia areata and atopic dermatitis.

Ryan Jacobs, MD, lymphoma division director at Atrium Health Levine Cancer Institute, explains the design and objectives of the phase 2 CAPTIVATE study comparing ibrutinib and venetoclax in patients with chronic lymphocytic leukemia (CLL).

Patients with moderate-to-severe plaque psoriasis experienced early and sustained improvements through 108 weeks of treatment.

The Society for Pediatric Dermatology (SPD) Annual Meeting focused on different aspects of pediatric dermatology, including topical treatments, technology, and misinformation.

Various speakers comment on why meetings like the Society for Pediatric Dermatology (SPD) 2024 Annual Meeting are important for the advancement of pediatric dermatology.

In this interview from our coverage of the European Hematology Association 2024 Congress, we spoke with Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd, executive vice president and chief medical officer of the CLL Society and himself a survivor of chronic lymphocytic leukemia (CLL), to discuss treatment advancements and the importance of addressing both unmet needs and patient treatment preferences.

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, details results from the ALKS 2680 trial and the study's next steps.

Timothy Caulfield, JD, research director of the Health Law Institute at the University of Alberta, discusses strategies for building trust, overcoming cultural and language barriers, and enhancing interdisciplinary collaboration in pediatric dermatology at the Society of Pediatric Dermatology conference.

We recently spoke with Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, about his team’s interim analysis of their dose-escalation study of glofitamab against relapsed/refractory B-cell non-Hodgkin lymphoma.

Experts in dermatology presented ways in which biologic therapies can be given and the duration of treatment when used in pediatric patients with skin conditions.

Timothy Caulfield, JD, research director of the Health Law Institute at the University of Alberta, takes a look at the major sources spreading dermatology misinformation to children, including social media.

Nichole Halliburton, APRN, CNP, a family nurse practitioner at the Cincinnati Children's Hospital Medical Center, explains the ways that patient education, parents and caregivers, and emerging technologies can help improve the quality of pediatric dermatology care.

Rebecca Flynn, MSN, APRN, CPNP-PC, a nurse practitioner (NP) at Children's Mercy Kansas City Dermatology, explained the roles that NPs and advanced practice providers (APPs) can fulfill in ensuring the efficiency of triage systems in a pediatric dermatology clinic.